What are the effects of commonly used treatments for chronic obstructive pulmonary disease (COPD) on patient outcomes?
S t u d y s e l e c t i o n a n d a s s e s s m e n t
Studies were selected if they were Englishlanguage, randomized controlled trials (RCTs) with ≥ 3 months of follow-up in adults with COPD and assessed long-acting (LA) β 2 -agonists (β 2 As); LA inhaled anticholinergics (tiotropium); combined shortacting (SA) β 2 As and SA anticholinergics; inhaled corticosteroids; combined inhaled corticosteroids and LAβ 2 As; pulmonary rehabilitation (with ≥ 6-wk follow-up); longterm nocturnal noninvasive mechanical ventilation; domiciliary oxygen therapy; or disease management (any combination of patient education, enhanced follow-up, and self-management sessions). Analysis was restricted to RCTs with blinded {only drug interventions where placebo was possible}* ascertainment of outcomes, complete or near-complete {> 90%}* follow-up data, and well-balanced baseline characteristics in treatment and control groups. 
M a i n r e s u l t s
The results are summarized in the Table. C o n c l u s i o n
In patients with chronic obstructive pulmonary disease, long-acting (LA) β 2 -agonists (β 2 As) and inhaled corticosteroids, with and without LAβ 2 As, reduce exacerbations, but not mortality. *Information provided by author. 
Sources of funding: Canadian Institutes of Health

C o m m e n t a r y
The review by Sin and colleagues covers a wide range of treatments for COPD. Breadth is achieved at the expense of detail, but the authors provide a useful overview. A major criticism of respiratory medicine has been the absence of large, long-term studies, unlike the field of cardiology.
In the controversial area of inhaled corticosteroid therapy for COPD, an attempt was made to rectify this paucity with several reasonably large studies that lasted ≥ 3 years. These studies provided some important answers, but still left unanswered questions. 2 meta-analyses (1, 2) published in 2003 found a slower decline in FEV 1 with inhaled corticosteroids compared with placebo, but the difference was < 10 mL/y, and the authors came to opposite conclusions on the importance of the finding. These meta-analyses included more studies than the review by Sin and colleagues, but the lack of available details makes comparisons difficult.
Recent studies of COPD have concentrated on clinically relevant outcomes, such as exacerbations, quality of life, and admissions, although definitions of exacerbations vary. LAβ 2 As, tiotropium, and inhaled corticosteroids all reduce exacerbations by 20% to 30% relative to placebo. The added benefits of combination therapies on various endpoints are difficult to extricate and need further study. Corticosteroids seem to add to the effect of LAβ 2 As. The results provide a good case for LAβ 2 As or tiotropium in patients with more than mild COPD and inhaled corticosteroids in patients with more severe disease.
Good evidence exists on the benefits of rehabilitation in the short to medium term, although there is uncertainty on how to maintain the initial benefit, and many countries have difficulty providing adequate respiratory rehabilitation programs. Smoking cessation and long-term oxygen therapy are the only treatments that significantly improve the natural history and life expectancy of persons with COPD.
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